<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        45-4-01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ADALAT 60MG LA TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NIFEDIPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        modified-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        58.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAYER AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 527]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrauf Ibrahim Batterjee & Bros. Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C08CA05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Adalat LA contains nifedipine, which belongs to a group of medicines<br />called calcium antagonists</strong>.<br /><strong>Adalat LA is used to treat high blood pressure or angina</strong> (chest pain).<br />For high blood pressure: Adalat LA works by relaxing and expanding the<br />blood vessels. This makes the blood flow more easily and lowers blood<br />pressure. Lower blood pressure reduces the strain on your heart.<br />For angina: Adalat LA works by relaxing and expanding the arteries<br />supplying the heart. This allows more blood and oxygen to reach the<br />heart and decreases the strain on it. Your angina attacks will be less<br />severe and less frequent if there is less strain on the heart.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>do not take Adalat LA:</strong><br />&bull; If you have had a heart attack within the last month.<br />&bull; If you get a sudden angina attack. Adalat LA will not help relieve<br />symptoms of angina quickly.<br />&bull; If you have unstable angina.<br />&bull; If you are allergic to nifedipine, any other similar medicines (known<br />as dihydropyridines) or any of the other ingredients of this medicine<br />(listed in section 6).<br />&bull; If you are taking rifampicin, an antibiotic.<br />&bull; If you have a liver disease that prevents your liver from working<br />properly.<br />&bull; If you have inflammation of the bowel or intestines, such as Crohn&rsquo;s<br />disease.<br />&bull; If you have an obstruction or narrowing in your intestines, or have had<br />this in the past.<br />&bull; If you have ever had an obstruction in the gullet (the oesophagus - the<br />tube connecting the throat to the stomach).<br />&bull; If you have been told that you have a narrowing of the aortic heart<br />valve (stenosis).<br />&bull; If you have ever had a collapse caused by a heart problem (cardiogenic<br />shock), during which you became breathless, pale and had a cold<br />sweat and dry mouth.<br />&bull; If you have a &ldquo;Kock pouch&rdquo; (a surgically constructed intestinal reservoir<br />with an opening through the abdominal wall) in your gut.<br />&bull; If your blood pressure continues to rise despite treatment (malignant<br />hypertension).<br /><strong>&rarr; Tell your doctor and do not take Adalat LA if any of these apply to you.<br />Warnings and precautions</strong><br />Talk to your doctor before taking Adalat LA<br />&bull; If you have low blood pressure and you were prescribed Adalat LA for<br />your angina. Your blood pressure may be decreased further by this<br />treatment.<br />&bull; If you have a heart condition where your heart cannot cope with<br />increased strain (poor cardiac reserve).<br />&bull; If you are pregnant.<br />&bull; If you are breast-feeding. If you need to take Adalat LA, you should<br />stop breast-feeding before you start to take this medicine.<br />&bull; If you are a diabetic. The treatment for your diabetes may need to be<br />adjusted. If you have any questions about this, ask your doctor.<br />&bull; If you are on kidney dialysis. If you have a very high blood pressure<br />and a low blood volume, you might experience a sudden drop in blood<br />pressure when you take Adalat LA.<br />&bull; If your liver is not working properly. Your doctor may need to do some<br />blood tests. You may also be given a lower dose of Adalat LA.</p><p><strong>&rarr; Talk to your doctor before you take Adalat LA if any of these apply to you.<br />tell your doctor:</strong><br />&bull; If your chest pain (angina) gets worse (comes on more often or more<br />severely) over a matter of hours or days. You may be advised not to<br />take Adalat LA.<br />&bull; If you have chest pains after taking your first dose of Adalat LA. Your<br />doctor may wish to change your treatment.<br />&bull; If you notice increased breathlessness.<br />&bull; If you notice swelling of the ankles.<br /><strong>&rarr; Tell your doctor before you take the next dose if any of these apply to you.<br />Also tell your doctor:</strong><br />&bull; If you are giving a urine sample. Adalat LA may interfere with the<br />results of certain urine tests.<br />&bull; If you are to have a barium contrast x-ray (barium meal). These tablets<br />may affect the results of the test.<br />&bull; If you are a man who has been unable to father a child by in vitro<br />fertilisation. Drugs like Adalat LA have been shown to impair sperm<br />function.<br /><strong>Other medicines and Adalat LA<br />Tell your doctor</strong> if you are taking, have recently taken or might take any<br />other medicines.<br />Some medicines may affect the way Adalat LA works. tell your doctor if<br />you are taking:<br />&bull; Other medicines to treat high blood pressure.<br />&bull; Rifampicin (an antibiotic).<br />&bull; Cimetidine (to treat stomach ulcers).<br />&bull; Digoxin, diltiazem, quinidine or beta-blockers (to treat heart<br />conditions).<br />&bull; Quinupristin/dalfopristin (a combination antibiotic).<br />&bull; Phenytoin, carbamazepine or valproic acid (to treat epilepsy).<br />&bull; Cisapride (to treat reduced movements of the gullet and stomach).<br />&bull; Magnesium sulphate injections during pregnancy (may cause a severe<br />fall in blood pressure).<br />&bull; Erythromycin (an antibiotic).<br />&bull; Ketoconazole, itraconazole or fluconazole (anti-fungal medicines).<br />&bull; Indinavir, nelfinavir, ritonavir, saquinavir or amprenavir (to treat HIV).<br />&bull; Fluoxetine or nefazodone (to treat depression).<br />&bull; Tacrolimus (to prevent the rejection of transplanted organs).<br />&bull; Phenobarbital (usually used to treat insomnia or anxiety).<br /><strong>Adalat LA with food and drink</strong><br />You can take Adalat LA with or without food.<br /><strong>Do not drink grapefruit juice or eat grapefruit while taking Adalat LA.</strong><br />Do not start taking Adalat LA within 3 days of drinking grapefruit juice or<br />eating grapefruit. Tell your doctor if you have had grapefruit or grapefruit<br />juice in this time. Also, do not drink grapefruit juice or eat grapefruit<br />whilst taking Adalat LA. Grapefruit juice is known to increase the blood<br />levels of the active ingredient, nifedipine. This effect can last for at least<br />3 days.<br />One tablet of Adalat LA 60 mg contains 48 mg salt (sodium chloride). <strong>tell<br />your doctor if you are on a low-salt diet.<br />Pregnancy and breast-feeding</strong><br />If you are pregnant, think you may be pregnant or are planning to have a<br />baby, <strong>ask your doctor for advice before taking this medicine.</strong><br />You may be able to use Adalat LA but only after special consideration and<br />agreement by your doctor.<br /><strong>do not take Adalat LA if you are breast-feeding. </strong>If you need to take<br />Adalat LA, you should stop breast-feeding before you start taking this<br />medicine.<br /><strong>driving and using machines</strong><br />Adalat LA may make you feel dizzy, faint, extremely tired or have visual<br />disturbances. Do not drive or operate machinery if you are affected in this<br />way.<br />This may be more likely when you first start treatment, if you change<br />tablets, or if you have drunk alcohol.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Adalat LA is specially formulated so that you only have to take one dose<br />each day.<br />Always take this medicine exactly as your doctor has told you. Check with<br />your doctor if you are not sure.<br />&bull;<strong> dose for high blood pressure</strong>: the usual dose is 1 tablet, once a day.<br /><strong>&bull; dose for angina: </strong>the dose depends on your individual requirements.<br />Your doctor will decide how much you should take.<br /><strong>&bull; swallow the tablets whole. do not bite, chew or break them</strong> &ndash; if<br />you do they will not work properly. If you have difficulty swallowing<br />tablets, consult your doctor as he or she may wish to change your<br />medicine.<br /><strong>&bull; Continue to take these tablets</strong> for as long as your doctor has told you<br />to.<br />Take your dose at the same time each day, preferably in the morning.<br />Take your tablets with a glass of water. Do not take them with grapefruit<br />juice.<br />You can take Adalat LA with or without food.<br />You may see what looks like a complete tablet in the toilet or in your<br />stools. This is normal &ndash; it&rsquo;s the outer shell of the tablet which is not<br />digested by the body.<br /><strong>use in children and adolescents:</strong><br />Adalat LA is not recommended for use in children and adolescents below<br />18 years of age, because there are only limited data on the safety and efficacy in this population.<br /><strong>If you take more Adalat LA than you should</strong><br /><strong>&rarr; Get medical help immediately.</strong> If possible, take your tablets or the<br />box with you to show the doctor.<br />Taking too many tablets may cause your blood pressure to become too<br />low and your heartbeats to speed up or slow down. It may also lead to<br />an increase in your blood sugar level or an increase in the acidity of your<br />blood, swelling in the lungs, low blood oxygen levels and disturbances in<br />consciousness, possibly leading to unconsciousness.<br /><strong>If you forget to take Adalat LA</strong><br />Take your normal dose immediately and continue taking your tablets at<br />the usual time of day, waiting at least 12 hours before taking the next<br />dose.<br />Do not take a double dose to make up for a forgotten dose.<br />If you have any further questions on the use of this medicine, ask your<br />doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />serious side effects<br />If you notice:<br />&bull; Severe, sudden generalised allergic reaction including very rarely lifethreatening<br />shock (e.g. difficulty in breathing, drop of blood pressure,<br />fast pulse), swelling (including potentially life-threatening swelling of<br />the airway)<br />&bull; other allergic reactions causing swelling under the skin (possibly<br />severe and including swelling of the larynx that may result in a lifethreatening<br />outcome)<br />&bull; fast heart beat (tachycardia)<br />&bull; shortness of breath (frequency not known) or difficulty breathing<br />&bull; mild to moderate allergic reactions<br />&bull; itching (possibly severe), a rash or hives<br /><strong>&rarr; Contact your doctor immediately and do not take the next dose</strong><br />as these may be the first signs of allergic reaction which may become<br />severe.<br /><strong>If you develop:</strong><br />&bull; a skin reaction or blistering/peeling of the skin and/or mucosal<br />reactions (in the mouth/nose or at the penis/vagina) (Toxic Epidermal<br />Necrolysis)<br /><strong>&rarr; Contact your doctor immediately before you continue treatment</strong><br />as these may be signs of a severe reaction.<br /><strong>Less serious side effects</strong><br />Apart from the side effects listed above, these are the other side effects of<br />Adalat LA, starting with the more common ones:<br /><strong>Common side effects </strong>(These may affect up to 1 in 10 people)<br />&bull; headache<br />&bull; flushing<br />&bull; general feeling of being unwell<br />&bull; constipation<br />&bull; swelling, particularly of the ankles and legs<br />uncommon side effects (These may affect up to 1 in 100 people)<br />&bull; stomach pain (abdominal pain)<br />&bull; unspecific pain<br />&bull; chills<br />&bull; low blood pressure when standing up (symptoms include fainting,<br />dizziness, light headedness, occasional palpitations, blurred vision and<br />sometimes confusion)<br />&bull; fainting<br />&bull; irregular heartbeat (palpitations)<br />&bull; dry mouth<br />&bull; indigestion or upset stomach<br />&bull; wind (flatulence)<br />&bull; feeling sick (nausea)<br />&bull; muscle cramps<br />&bull; joint swelling<br />&bull; sleep disorders<br />&bull; anxiety or nervousness<br />&bull; reddening of the skin<br />&bull; nose bleeds<br />&bull; nasal congestion<br />&bull; sensation of spinning or whirling motion (vertigo)<br />&bull; migraine<br />&bull; dizziness<br />&bull; trembling<br />&bull; increase in the need to pass water (urinate)<br />&bull; painful or difficult urination<br />&bull; inability to achieve or maintain an erection (impotence)<br />&bull; blurred vision<br />&bull; temporary increase in certain liver enzymes<br /><strong>Rare side effects</strong> (These may affect up to 1 in 1,000 people)<br />&bull; pins and needles<br />&bull; inflammation of the gums, tender or swollen gums, bleeding gums<br /><strong>other side effects</strong> (Frequency not known: frequency cannot be estimated<br />from the available data)<br />&bull; stomach pain or distress caused by a mass of foreign material found in<br />the stomach which may require surgery for removal<br />&bull; difficulty swallowing<br />&bull; abdominal pain, caused by obstruction of the gut or ulcers in the gut<br />&bull; vomiting<br />&bull; a reduction in the number of white blood cells (leucopenia)<br />&bull; a more severe decrease in a specific class of white blood cell<br />(agranulocytosis)<br />&bull; increased blood sugar (hyperglycaemia)<br />&bull; decreased skin sensitivity (hypoaesthesia)<br />&bull; drowsiness (somnolence)<br />&bull; eye pain<br />&bull; chest pain (angina pectoris)<br />&bull; heartburn or indigestion (gastroesophageal sphincter insufficiency)<br />&bull; yellowing of the whites of the eyes or skin (jaundice)<br />&bull; sensitivity to light (photosensitivity allergic reaction)<br />&bull; small, raised areas of bleeding in the skin (palpable purpura)<br />&bull; joint pain<br />&bull; muscle pain<br />All of these symptoms usually go away when treatment with Adalat LA is<br />stopped.<br /><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor or pharmacist. This includes<br />any possible side effects not listed in this leaflet. By reporting side effects<br />you can help provide more information on the safety of this medicine.<br /><strong>to report any side effect(s):</strong><br />National Pharmacovigilance and Drug Safety Center (NPC).<br />Fax: + 966 - 11 - 205 - 7662.<br />Call NPC at +966 - 11 - 2038222,<br />Ext.: 2317 - 2356 - 2353 - 2354 - 2334 - 2340.<br />Toll - free: 8002490000.<br />E - mail: npc.drug@sfda.gov.sa.<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Not to be stored above 25&deg;C.<br />Store your medicine in its original container. Protect from strong light and<br />only remove the tablet from the blister strip when you are about to take it.<br />Do not use this medicine after the expiry date which is stated on both the<br />outer carton and on each blister strip of tablets after EXP. The expiry date<br />refers to the last day of that month.<br />Do not throw away any medicines via wastewater or household waste.<br />Ask your pharmacist how to throw away medicines you no longer use.<br />These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Adalat LA contains</strong><br />Adalat LA tablets contain the active ingredient, nifedipine.<br />Adalat LA tablets also contain cellulose acetate, ferric oxide (E172),<br />hydroxypropyl cellulose, hydroxypropyl methylcellulose, macrogol,<br />magnesium stearate, propylene glycol, titanium oxide (E171). Each 60<br />mg tablet also contains 48 mg of sodium chloride (salt) to be taken into<br />consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Each prolonged-release tablet contains 60 mg of nifedipine. Each tablet is
pink and round with a laser hole on one side and marked ‘Adalat 60’.
Each pack contains 30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer</strong><br />Bayer AG<br />Kaiser-Wilhelm-Allee 1<br />51373 Leverkusen, Germany.<br /><strong>Secondary Packed by:</strong><br />DEEF Pharmaceutical Ind. Co.,<br />Saudi Arabia - Al Qassim</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in August 2016.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي أدالات ال ايه على نيفيدبين والذي ينتمي إلى مجموعة من الأدوية تعرف باسم مناهضات الكالسيوم.<br /><strong>يستخدم أدالات ال ايه لعلاج ارتفاع ضغط الدم أو الذبحة الصدرية</strong> (ألم في الصدر).<br /><u>لضغط الدم المرتفع</u>: يعمل أدالات ال ايه عن طريق إرخاء وتوسيع الأوعية الدموية. وهذا يجعل الدم يتدفق بسهولة أكثر ويخفض ضغط الدم. ضغط الدم المنخفض يقلل الجهد من على قلبك.<br /><u>للذبحة الصدرية</u>: يعمل أدالات ال ايه عن طريق إرخاء وتوسيع الشرايين التي تمد القلب بالدم. وهذا يسمح للمزيد من الدم والأكسجين أن يصل إلى القلب مما يقلل الجهد من عليه. ستكون نوبات الذبحة لديك أقل حدة وأقل تواترا إذا كان الجهد على القلب أقل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول أدالات ال ايه:</strong></p><ul><li>إذا كنت قد تعرضت لنوبة قلبية خلال الشهر الماضي.</li><li>إذا كنت تصاب بنوبة ذبحة مفاجئة. أدالات ال ايه لن يساعد في تخفيف أعراض الذبحة بسرعة.</li><li>إذا كنت مصابا بذبحة غير مستقرة.</li><li>إذا كنت مصابا بالحساسية تجاه نيفيديبين، أو أي أدوية أخرى مماثلة (والمعروفة بثنائي هيدرو البيريدين) أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</li><li>إذا كنت تتناول ريفامباسين، مضاد حيوي.</li><li>إذا كنت مصابا بمرض في الكبد يمنع كبدك من العمل بشكل صحيح.</li><li>إذا كنت مصابا بالتهابات في الأحشاء أو الأمعاء، مثل مرض كرون.</li><li>إذا كنت مصابا بانسداد أو ضيق في أمعائك، أو إذا كنت قد أصبت بذلك في السابق.</li><li>إذا كنت قد أصبت في أي وقت مضى بانسداد في المرئ (المرئ - القناة الرابطة بين الحنجرة والمعدة)</li><li>إذا كان قد قيل لك أنك مصاب بضيق في صمام القلب الأبهر (الأورطي) (تضيق الأوعية الدموية).</li><li>إذا كنت قد أصبت في أي وقت مضى بانخماص (انهيار) ناجم عن مشكلة في القلب (صدمة قلبية)، والتي أصبحت خلالها لاهثا، شاحبا وأصبت بعرق بارد وجفاف الفم.</li><li>إذا كان لديك &laquo;جيبة كوخ&raquo; (خزان معوي تم انشاؤه جراحيا مع فتحة من خلال جدار البطن) في أمعائك.</li><li>إذا كان ضغط الدم لديك مستمرا في الارتفاع على الرغم من العلاج (ارتفاع ضغط الدم الخبيث).</li></ul><p><strong>أخبر طبيبك ولا تتناول أدالات ال ايه إذا كان أي من هذه الأعراض ينطبق عليك.</strong><br /><strong>التحذيرات والاحتياطات</strong><br />تحدث إلى طبيبك قبل تناول أدالات ال ايه</p><ul><li>إذا كنت مصابا بضعط دم منخفض وتم وصف أدالات ال ايه لعلاج الذبحة لديك. فقد ينخفض ضعط الدم أكثر بهذا العلاج.</li><li>إذا كنت مصابا بمرض في القلب حيث لا يستطيع قلبك التعامل مع زيادة الجهد عليه (مدخر قلبي ضعيف).</li><li>إذا كنت حاملا.</li><li>إذا كنت ترضعين رضاعة طبيعية. إذا كنت بحاجة لتناول أدالات ال ايه فينبغي عليك التوقف عن الرضاعة الطبيعية قبل البدء في تناول هذا الدواء.</li><li>إذا كنت مصابا بمرض السكر. قد يحتاج علاج مرض السكر الخاص بك إلى تعديل. إذا كان لديك أي أسئلة بهذا الشأن، اسأل طبيبك.</li><li>إذا كنت تقوم بعمل غسيل كلى. إذا كنت مصابا بضغط دم مرتفع جدا وحجم الدم منخفض، فقد تواجه انخفاض مفاجئ في ضغط الدم عند تناول أدالات ال ايه.</li><li>إذا كان كبدك لا يعمل بشكل طبيعي. قد يحتاج طبيبك إلى إجراء بعض اختبارات الدم. كما يمكن أيضا اعطاؤك جرعة أقل من أدالات ال ايه.</li></ul><p><strong>تحدث مع طبيبك قبل تناول أدالات ال ايه إذا كان أي من هذه الأعراض ينطبق عليك.</strong><br /><strong>أخبر طبيبك:</strong></p><ul><li>إذا ازداد ألم الصدر (الذبحة) لديك سوءا (تصاب بها في أحيان أكثر أو بحدة أكثر) على مدى ساعات أو أيام. قد تُنصح بعدم تناول أدالات ال ايه.</li><li>إذا شعرت بآلام في الصدر بعد تناول أول جرعة من أدالات ال ايه. قد يرغب طبيبك في تغيير علاجك.</li><li>إذا لاحظت زيادة في صعوبة التنفس.</li><li>إذا لاحظت تورما في الكاحلين.</li></ul><p><strong>أخبر طبيبك قبل تناول جرعتك التالية من أدالات ال ايه إذا كان أي من هذه الأعراض ينطبق عليك.</strong><br /><strong>أخبر طبيبك أيضا:</strong></p><ul><li>إذا كنت ستقدم عينة بول. قد يتداخل أدالات ال ايه مع نتائج بعض اختبارات البول.</li><li>إذا كنت ستقوم بإجراء أشعة سينية بتباين الباريوم (وجبة باريوم)، فإن هذه الأقراص من الممكن أن تؤثر على نتائج الاختبار.</li><li>إذا كنت رجلا غير قادر على إنجاب طفل عن طريق الإخصاب في المختبر. قد تبين أن العقاقير مثل أدالات ال ايه تعيق وظيفة الحيوانات المنوية.</li></ul><p><strong>الأدوية الأخرى وأدالات ال ايه</strong><br /><strong>أخبر طبيبك </strong>إذا كنت تتناول أو قد تناولت مؤخرا أو قد تتناول أي أدوية أخرى.<br />بعض الأدوية قد تؤثر على طريقة عمل أدالات ال ايه. أخبر طبيبك إذا كنت تتناول:</p><ul><li>أدوية أخرى لعلاج ضغط الدم المرتفع.</li><li>ريفامبيسين (مضاد حيوي).</li><li>سيميتيدين (لعلاج قرح المعدة).</li><li>ديجوكسين، ديلتيازيم، كينيدين أو حاصرات بيتا (لعلاج أمراض القلب).</li><li>كينوبريستين / دالفوبريستين (مضاد حيوي مركب).</li><li>فينيتوين، كاربامازيبين أو حمض الفالبرويك (لعلاج الصرع).</li><li>سيسابريد (لعلاج انخفاض حركة المريء والمعدة).</li><li>حقن سلفات المغنسيوم أثناء الحمل (قد يتسبب في انخفاض حاد في ضغط الدم).</li><li>اريثروميسين (مضاد حيوي).</li><li>كيتوكونازول، إيتراكونازول أو فلوكونازول (أدوية مضادة للفطريات).</li><li>إندينافير، نلفينافير، ريتونافير، ساكينافير أو أمبرينافير (لعلاج فيروس نقص المناعة البشرية).</li><li>فلوكستين أو نيفازودون (لعلاج الاكتئاب).</li><li>تاكروليماس (لمنع رفض الأعضاء المزروعة).</li><li>فينوباربيتال (يستخدم عادة لعلاج الأرق أو القلق).</li></ul><p><strong>أدالات ال ايه مع الطعام والشراب</strong><br />يمكنك تناول أدالات ال ايه مع أو بدون طعام.<br /><strong>لا تشرب عصير الجريب فروت أو تتناول الجريب فروت أثناء تناول أدالات ال ايه.</strong><br />لا تبدأ في تناول أدالات ال ايه في خلال 3 أيام من شربك لعصير الجريب فروت أو تناولك للجريب فروت. أخبر طبيبك إذا كنت قد تناولت الجريب فروت أو عصير الجريب فروت في هذا الوقت. أيضا لا تشرب عصير الجريب فروت أو تتناول الجريب فروت أثناء تناولك لأدالات ال ايه. من المعروف أن عصير الجريب فروت يزيد من تركيز مستويات الدم من المادة الفعالة نيفيديبين. ومن الممكن أن يستمر هذا التأثير لمدة 3 أيام على الأقل.<br />يحتوي قرص واحد من أدالات ال ايه 60 على 48 مجم من الملح (كلوريد الصوديوم). أخبر طبيبك إذا كنت على نظام غذائي منخفض الملح.<br /><strong>الحمل والرضاعة الطبيعية</strong><br />إذا كنت حاملا أو كنت تعتقدين أنك حامل أو كنت تخططين لإنجاب طفل، استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.<br />قد يكون بإمكانك استخدام أدالات ال ايه ولكن فقط بعد اعتبارات خاصة واتفاق مع طبيبك<br />لا تتناولي أدالات ال ايه إذا كنت ترضعين طبيعيا إذا كنت بحاجة لتناول أدالات ال ايه فينبغي عليك التوقف عن الرضاعة الطبيعية قبل البدء في تناول هذا الدواء.<br /><strong>القيادة واستخدام الآلات</strong><br />من الممكن لأدالات ال ايه أن يجعلك تشعر بالدوار أو الإغماء أو أن تصبح متعبا للغاية أو تصاب باضطرابات بصرية. لا تقود السيارة أو تشغل الآلات إذا تأثرت بهذه الطريقة.<br />قد يكون هذا أكثر احتمالا عند بدء العلاج في الأول، أو إذا قمت بتغيير الأقراص، أو إذا كنت قد تناولت كحوليات.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تم صياغة أدالات ال ايه خصيصا بحيث تتناول جرعة واحدة كل يوم.<br />تناول هذا الدواء دائما كما أخبرك طبيبك بالضبط. راجع طبيبك إذا لم تكن متأكدا.</p><ul><li>الجرعة لضغط الدم المرتفع: الجرعة المعتادة هي قرص واحد مرة واحدة يوميا.</li><li>الجرعة للذبحة الصدرية: تعتمد الجرعة على متطلباتك الفردية. سيقرر لك طبيبك كم ينبغي أن تتناول.</li><li>ابتلع الأقراص كاملة. لا تقم بعضها أو مضغها أو كسرها - إذا فعلت ذلك فلن تقوم الأقراص بعملها بشكل صحيح. إذا وجدت صعوبة في ابتلاع الأقراص، استشر طبيبك حيث قد يرغب في تغيير دواءك.</li><li>استمر في تناول هذه الأقراص طالما أخبرك طبيبك بذلك. تناول جرعتك في نفس الموعد كل يوم ويفضل أن يكون في الصباح.</li></ul><p>تناول أقراصك مع كوب من الماء. لا تتناولها مع عصير جريب فروت. يمكنك تناول أدالات ال ايه مع أو بدون طعام.<br />قد تلاحظ ما يبدو كقرص كامل في المرحاض أو في البراز. هذا طبيعي - إنه الغلاف الخارجي للقرص والذي لا يتم هضمه بواسطة الجسم.<br /><strong>الاستخدام في الأطفال والمراهقين:</strong><br />لا ينصح باستخدام أدالات ال ايه في الأطفال والمراهقين أقل من 18 سنة، لأن هناك بيانات محدودة فقط عن السلامة والفعالية في هذه الفئة من المرضى.<br /><strong>إذا تناولت أدالات ال ايه أكثر مما ينبغي</strong><br /><strong>اسعى للحصول على مساعدة طبية على الفور</strong>.إذا كان ممكنا، خذ معك الأقراص أو العلبة لتريها للطبيب.<br />إن تناول الكثير من الأقراص قد يتسبب في انخفاض ضغط دمك بشدة وتسريع أو إبطاء دقات قلبك. كما قد يؤدي أيضا إلى ارتفاع مستوى السكر في الدم أو إلى زيادة حموضة الدم وتورم الرئتين وانخفاض مستويات الأكسجين في الدم واضطرابات في الوعي مما قد يؤدي إلى فقدان الوعي.<br /><strong>إذا نسيت تناول أدالات ال ايه</strong><br />تناول جرعتك المعتادة على الفور واستمر في تناول الأقراص في موعدها المعتاد من اليوم، والانتظار ما لا يقل عن 12 ساعة قبل تناول الجرعة التالية.<br />لا تتناول جرعة مضاعفة لتعويض جرعة فائتة.<br />إذا كان لديك المزيد من الأسئلة عن استخدام هذا الدواء، اسأل طبيبك.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، من الممكن أن يتسبب هذا الدواء في آثار جانبية، وإن لم تكن تصيب الجميع.<br /><strong>آثار جانبية خطيرة إذا لاحظت:</strong></p><ul><li>رد فعل تحسسي عام مفاجئ شديد، بما في ذلك صدمة مهددة للحياة تحدث نادرا جدا (مثل صعوبة في التنفس، وانخفاض في ضغط الدم، ونبض سريع)، وتورم (بما في ذلك تورم في مجرى الهواء من المحتمل أن يكون مهددا الحياة )</li><li>تفاعلات تحسسية أخرى بما في ذلك تورم تحت الجلد (من الممكن أن تكون شديدة وتتضمن تورم في الحنجرة قد يؤدي إلى نتيجة مهددة للحياة)</li><li>ضربات القلب السريع (عدم انتظام دقات القلب)</li><li>ضيق في التنفس (تكرارية غير معروفة) أو صعوبة في التنفس</li><li>ردود فعل تحسسية خفيفة إلى معتدلة</li><li>حكة (ربما شديدة)، طفح جلدي أو شرى</li></ul><p>ا<strong>تصل بطبيبك على الفور ولا تتناول جرعتك التالية</strong> لأن هذه قد تكون أولى علامات رد الفعل التحسسي الذي قد يصبح شديدا.<br /><strong>إذا عانيت من:</strong></p><ul><li>رد فعل جلدي أو تقرح / تقشير في الجلد و / أو ردود فعل مخاطية (في الفم / الأنف أو في القضيب / المهبل) (تقشر الأنسجة المتموتة البشروية التسممي)</li></ul><p><strong>اتصل بطبيبك على الفور قبل الاستمرار في العلاج</strong> لأن هذه قد تكون علامات على رد فعل شديد.<br /><strong>آثار جانبية أقل خطورة</strong><br />بعيدا عن الآثار الجانبية المذكورة أعلاه، هذه بعض الآثار الجانبية الأخرى لأدالات ال ايه، بدءا من الآثار الأكثر شيوعا:<br /><strong>آثار جانبية شائعة</strong>: (هذه قد تصيب حتى 1 من 10 أشخاص)</p><ul><li>صداع</li><li>احمرار</li><li>شعور عام بالتعب</li><li>إمساك</li><li>تورم وخاصة في الكاحلين والساقين</li></ul><p><strong>آثار جانبية غير شائعة: </strong>(هذه قد تصيب حتى 1 من 100 شخص)</p><ul><li>ألم في المعدة (وجع البطن)</li><li>ألم غير محدد</li><li>قشعريرة</li><li>انخفاض ضغط الدم عند الوقوف (الأعراض تشمل الإغماء، والدوخة، والدوار، والخفقان في بعض الأحيان، وعدم وضوح الرؤية والتشوش أحيانا)</li><li>الإغماء</li><li>عدم انتظام ضربات القلب (خفقان)</li><li>جفاف الفم</li><li>عسر الهضم أو اضطراب في المعدة</li><li>ريح (انتفاخ البطن)</li><li>الشعور بالإعياء (الغثيان)</li><li>تشنجات العضلات.</li><li>تورم المفاصل</li><li>اضطرابات النوم</li><li>القلق أو العصبية</li><li>احمرار الجلد</li><li>نزيف الأنف</li><li>احتقان الأنف</li><li>الاحساس بالدوران أو حركة دوامة (دوار)</li><li>صداع نصفي (شقيقة)</li><li>دوخة</li><li>ارتجاف</li><li>زيادة الحاجة إلى التبول</li><li>صعوبة أو ألم في التبول</li><li>عدم القدرة على تحقيق أو الحفاظ على الانتصاب (عجز جنسي)</li><li>تشوش الرؤية</li><li>زيادة مؤقتة في بعض إنزيمات الكبد</li></ul><p><strong>آثار جانبية نادرة</strong>: (هذه قد تصيب حتى 1 من 1,000 شخص)</p><ul><li>شعور بوخز (مسامير ودبابيس)</li><li>التهاب اللثة، ألم أو تورم في اللثة، نزيف اللثة</li></ul><p><strong>آثار جانبية أخرى:</strong> (تكرار غير معروف: حالات لا يمكن تقديرها من البيانات المتاحة)</p><ul><li>ألم أو ضيق في المعدة ناجم عن كتلة من المواد الغريبة الموجودة في المعدة والتي قد تطلب عملية جراحية لإزالتها</li><li>صعوبة البلع</li><li>ألم في البطن ناجم عن انسداد في الأمعاء أو قرحة في القناة الهضمية</li><li>قئ</li><li>انخفاض في عدد خلايا الدم البيضاء (قلة الكريات البيض)</li><li>انخفاض أكثر حدة في فئة معينة من خلايا الدم البيضاء (ندرة المحببات)</li><li>ارتفاع سكر الدم&nbsp;</li><li>انخفاض حساسية الجلد (نقص الحس)</li><li>وسن (نعاس)</li><li>ألم في العين</li><li>ألم في الصدر (ذبحة صدرية)</li><li>حرقة في المعدة أو عسر هضم (قصور العاصرة المعدي المريئي)</li><li>اصفرار بياض العينين أو الجلد (اليرقان)</li><li>الحساسية للضوء (رد فعل تحسسي للضوء)</li><li>مناطق بارزة وصغيرة من النزف في الجلد (الفرفرية الملموسة)</li><li>ألم المفاصل</li><li>ألم العضلات</li></ul><p>جميع هذه الأعراض تختفي عند توقف العلاج بأدالات ال ايه.<br /><strong>الإبلاغ عن الآثار الجانبية</strong><br />إذا أصبت بأي أعراض جانبية، أخبر طبيبك أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة وغير مذكورة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.<br /><strong>للإبلاغ عن الأعراض الجانبية:</strong><br />المركز الوطني للتيقظ و السلامة الدوائية<br />فاكس: 7662 &ndash; 205 &ndash; 11 &ndash; 966 +<br />للاتصال بالإدارة التنفيذية للتيقظ و إدارة الأزمات.&nbsp;<br />هاتف: 2038222 &ndash; 11 &ndash; 966 + &nbsp;&nbsp;<br />تحويلة: 2353 &ndash; 2356 &ndash; 2317 &ndash; 2354 &ndash; 2334 &ndash; 2340<br />الهاتف المجاني: 8002490000<br />البريد الالكتروني: npc.drug@sfda.gov.sa&nbsp;<br />الموقع الالكتروني: www.sfda.gov.sa/npc<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيدا عن متناول ورؤية الأطفال. لا يُحفظ في درجة حرارة أكثر من 25 درجة مئوية<br />احفظ الدواء في عبوته الأصلیة. يحفظ بعيدا عن الضوء القوي وانزع القرص من الشريط فقط عندما تكون على وشك تناوله.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على كل من العلبة الخارجية وعلى كل شريط من شرائط الأقراص بعد كلمة تاريخ الإنتهاء &laquo;EXP&raquo;. تاريخ الانتهاء يشير إلى آخر يوم من ذلك الشهر.<br />لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحتوي أدالات ال ايه على المادة الفعالة نيفيديبين.<br />تحتوي أقراص أدالات ال ايه أيضا على خلات السليولوز، أكسيد الحديديك (E172)،هيدروكسي بروبيل سليولوز، هيدروكسي بروبيل ميثيل سليولوز، ماكروجول، ستيرات المغنيسيوم، بروبيلين جليكول، أكسيد التيتانيوم (E171). يحتوي كل قرص 60 مجم أيضا على 48 مجم من كلوريد الصوديوم (الملح) والذي ينبغي أن يؤخذ بعين الاعتبار من قبل المرضى المتبعون لنظام غذائي مراقب للصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يحتوي كل قرص ممتد الإطلاق على 60 مجم من نيفيديبين. كل قرص قرنفلي اللون وعلى شكل مستدير وبه ثقب بالليزر على إحدى الجهتين وعليه علامة &laquo;Adalat 60&raquo;. تحتوي كل عبوة على 30 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>المصنع</strong><br />باير ايه جي<br />1 طريق القيصر ويلهلم<br />51373 ليفركوزن، ألمانيا.</p><p><strong>التغليف الثانوي</strong><br />شركة ديف للصناعات الدوائية<br />المملكة العربية السعودية - القصيم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس 2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Adalat LA 60 mg prolonged-release tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each prolonged-release tablet contains 60 mg nifedipine.

	Each tablet contains a 10% overage of nifedipine to deliver the label claim.

	For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release tablet.

	Pink, round, convex prolonged-release tablet with a laser hole on one side and marked with Adalat 60.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For the treatment of all grades of hypertension.</p><p>&nbsp;</p><p>For the prophylaxis of chronic stable<strong> </strong>angina pectoris either as monotherapy or in combination with a beta-blocker.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Posology</u></em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In mild to moderate hypertension, the recommended initial dose is one 20 mg tablet once-daily.&nbsp; In severe hypertension, the recommended initial dose is one 30 mg tablet once-daily. If necessary, the dosage can be increased according to individual requirements up to a maximum of 90 mg once-daily.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the prophylaxis of angina pectoris, the recommended initial dose is one 30&nbsp;mg tablet once-daily. The dosage can be increased according to individual requirements up to a maximum of 90&nbsp;mg once-daily.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients in whom hypertension or anginal symptoms are controlled on Adalat capsules or Adalat retard may be safely switched to Adalat LA.&nbsp; Prophylactic anti-anginal efficacy is maintained when patients are switched from other calcium antagonists such as diltiazem or verapamil to Adalat LA.&nbsp; Patients switched from other calcium antagonists should initiate therapy at the recommended initial dose of 30&nbsp;mg Adalat LA once-daily.&nbsp; Subsequent titration to a higher dose may be initiated as warranted clinically.</p><p>&nbsp;</p><p>Co-administration with CYP 3A4 inhibitors or CYP 3A4 inducers may result in the recommendation to adapt the nifedipine dose or not to use nifedipine at all (see section 4.5).</p><p>&nbsp;</p><p><em>Duration of treatment</em></p><p>&nbsp;</p><p>Treatment may be continued indefinitely.</p><p>&nbsp;</p><p><em>Additional information on special populations</em></p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>The safety and efficacy of Adalat LA in children below 18 years has not been established. Currently available data for the use of nifedipine in hypertension are described in section 5.1</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Based on pharmacokinetic data for Adalat LA no dose adaptation in old people above 65 years is necessary.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Based on pharmacokinetic data, no dosage adjustment is required in patients with renal impairment (see section 5.2).</p><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p><em><u>Method of administration</u></em></p><p><strong><em>&nbsp;</em></strong></p><p>Oral use.</p><p>&nbsp;</p><p>The tablets should be swallowed whole with a glass of water, either with or without food.&nbsp; The tablets should be taken at approximately 24-hour intervals, i.e. at the same time each day, preferably during the morning.&nbsp; Adalat LA tablets must be swallowed whole; under no circumstances should they be bitten, chewed or broken up.</p><p>&nbsp;</p><p>Adalat LA should not be taken with grapefruit juice (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Adalat LA should not be administered to patients with known hypersensitivity to the active substance, or to other dihydropyridines because of the theoretical risk of cross-reactivity, or to any of the excipients listed in sections 4.4 and 6.1.
	
	Adalat LA should not be used in cases of cardiogenic shock, clinically significant aortic stenosis, unstable angina, or during or within one month of a myocardial infarction.

	Adalat LA should not be used for the treatment of acute attacks of angina.

	The safety of Adalat LA in malignant hypertension has not been established.

	Adalat LA should not be used for secondary prevention of myocardial infarction.

	Owing to the duration of action of the formulation, Adalat LA should not be administered to patients with hepatic impairment.

	Adalat LA should not be administered to patients with a history of gastro-intestinal obstruction, oesophageal obstruction, or any degree of decreased lumen diameter of the gastro-intestinal tract.

Adalat LA must not be used in patients with a Kock pouch (ileostomy after proctocolectomy).
	
	Adalat LA is contra-indicated in patients with inflammatory bowel disease or Crohn's disease.

	Adalat LA should not be administered concomitantly with rifampicin since effective plasma levels of nifedipine may not be achieved owing to enzyme induction (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adalat LA tablets must be swallowed whole; under no circumstances should they be bitten, chewed or broken up.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caution should be exercised in patients with hypotension as there is a risk of further reduction in blood pressure and care must be exercised in patients with very low blood pressure (severe hypotension with systolic blood pressure less than 90 mm Hg).</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adalat LA should not be used during pregnancy unless the clinical condition of the woman requires treatment with nifedipine. Adalat LA should be reserved for women with severe hypertension who are unresponsive to standard therapy (see section 4.6).</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Careful monitoring of blood pressure must be exercised when administering nifedipine with I.V. magnesium sulfate, owing to the possibility of an excessive fall in blood pressure, which could harm both mother and foetus. For further information regarding use in pregnancy, refer to section 4.6.</p><p>&nbsp;</p><p>Adalat LA is not recommended for use during breast-feeding because nifedipine has been reported to be excreted in human milk and the effects of nifedipine exposure to the infant are not known (see section 4.6).</p><p>&nbsp;</p><p>In patients with impaired liver function careful monitoring and, in severe cases, a dose reduction may be necessary.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adalat LA may be used in combination with beta-blocking drugs and other antihypertensive agents but the possibility of an additive effect resulting in postural hypotension should be borne in mind.&nbsp; Adalat LA will not prevent possible rebound effects after cessation of other antihypertensive therapy.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adalat LA should be used with caution in patients whose cardiac reserve is poor. Deterioration of heart failure has occasionally been observed with nifedipine.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetic patients taking Adalat LA may require adjustment of their control.</p><p>In dialysis patients with malignant hypertension and hypovolaemia, a marked decrease in blood pressure can occur.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nifedipine is metabolised via the cytochrome P450 3A4 system. Drugs that are known to either inhibit or to induce this enzyme system may therefore alter the first pass or the clearance of nifedipine (see section 4.5).</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drugs, which are known inhibitors of the cytochrome P450 3A4 system, and which may therefore lead to increased plasma concentrations of nifedipine include, for example:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; macrolide antibiotics (e.g., erythromycin)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-HIV protease inhibitors (e.g., ritonavir)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; azole antimycotics (e.g., ketoconazole)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the antidepressants, nefazodone and fluoxetine</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; quinupristin/dalfopristin</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; valproic acid</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cimetidine</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upon co-administration with these drugs, the blood pressure should be monitored and, if necessary, a reduction of the nifedipine dose should be considered.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As the outer membrane of the Adalat LA tablet is not digested, what appears to be the complete tablet may be seen in the toilet or associated with the patient&rsquo;s stools. Also, as a result of this, care should be exercised when administering Adalat LA to patients, as obstructive symptoms may occur. Bezoars can occur in very rare cases and may require surgical intervention.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In single cases, obstructive symptoms have been described without known history of gastrointestinal disorders.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A false positive effect may be experienced when performing a barium contrast x-ray.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For use in special populations see section 4.2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Drugs that affect nifedipine</u></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nifedipine is metabolised via the cytochrome P450 3A4 system, located both in the intestinal mucosa and in the liver. Drugs that are known to either inhibit or to induce this enzyme system may therefore alter the first pass (after oral administration) or the clearance of nifedipine (see Section 4.4).</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The extent as well as the duration of interactions should be taken into account when administering nifedipine together with the following drugs:</p><p>&nbsp;</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin: </em>Rifampicin strongly induces the cytochrome P450 3A4 system. Upon co-administration with rifampicin, the bioavailability of nifedipine is distinctly reduced and thus its efficacy weakened. The use of nifedipine in combination with rifampicin is therefore contraindicated (see Section 4.3).</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upon co-administration of known inhibitors of the cytochrome P450 3A4 system, the blood pressure should be monitored and, if necessary, a reduction in the nifedipine dose considered (see Sections 4.2 and 4.4). In the majority of these cases, no formal studies to assess the potential for a drug interaction between nifedipine and the drug(s) listed have been undertaken, thus far.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; D<u>rugs increasing nifedipine exposure:</u></p><p>&nbsp;</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; macrolide antibiotics (e.g., erythromycin)</em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-HIV protease inhibitors (e.g., ritonavir)</em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; azole anti-mycotics (e.g., ketoconazole)</em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluoxetine</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>nefazodone</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>quinupristin/dalfopristin</em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cisapride</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>valproic acid</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>cimetidine</em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diltiazem</em></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upon co-administration of inducers of the cytochrome P450 3A4 system, the clinical response to nifedipine should be monitored and, if necessary, an increase in the nifedipine dose considered. If the dose of nifedipine is increased during co-administration of both drugs, a reduction of the nifedipine dose should be considered when the treatment is discontinued.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Drugs decreasing nifedipine exposure:</u></p><p><em>&nbsp;</em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (see above)</em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin</em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine</em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenobarbital</em></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Effects of nifedipine on other drugs</u></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nifedipine may increase the blood pressure lowering effect of concomitant applied antihypertensives.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When nifedipine is administered simultaneously with &szlig;-receptor blockers the patient should be carefully monitored, since deterioration of heart failure is also known to develop in isolated cases.</p><p>&nbsp;</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin</em>: The simultaneous administration of nifedipine and digoxin may lead to reduced digoxin clearance and, hence, an increase in the plasma digoxin level. The patient should therefore be subjected to precautionary checks for symptoms of digoxin overdosage and, if necessary, the glycoside dose should be reduced.</p><p>&nbsp;</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quinidine: </em>Co-administration of nifedipine with quinidine may lower plasma quinidine levels, and after discontinuation of nifedipine, a distinct increase in plasma quinidine levels may be observed in individual cases. Consequently, when nifedipine is either additionally administered or discontinued, monitoring of the quinidine plasma concentration, and if necessary, adjustment of the quinidine dose are recommended. Blood pressure should be carefully monitored and, if necessary, the dose of nifedipine should be decreased.</p><p>&nbsp;</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tacrolimus</em>: Tacrolimus is metabolised via the cytochrome P450 3A4 system. Published data indicate that the dose of tacrolimus administered simultaneously with nifedipine may be reduced in individual cases. Upon co-administration of both drugs, the tacrolimus plasma concentrations should be monitored and, if necessary, a reduction in the tacrolimus dose considered.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Drug food interactions</u></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grapefruit juice inhibits the cytochrome P450 3A4 system. Administration of nifedipine together with grapefruit juice thus results in elevated plasma concentrations and prolonged action of nifedipine due to a decreased first pass metabolism or reduced clearance. As a consequence, the blood pressure lowering effect of nifedipine may be increased. After regular intake of grapefruit juice, this effect may last for at least three days after the last ingestion of grapefruit juice. Ingestion of grapefruit/grapefruit juice is therefore to be avoided while taking nifedipine (see Section 4.2).</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other forms of interaction</u></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nifedipine may increase the spectrophotometric values of urinary vanillylmandelic acid, falsely.&nbsp; However, HPLC measurements are unaffected.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nifedipine should not be used during pregnancy unless the clinical condition of the woman requires treatment with nifedipine (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In animal studies, nifedipine has been shown to produce embryotoxicity, foetotoxicity and teratogenicity (see section 5.3).</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There are no adequate well controlled studies in pregnant women.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; From the clinical evidence available a specific prenatal risk has not been identified, although an increase in perinatal asphyxia, caesarean delivery, as well as prematurity and intrauterine growth retardation have been reported. It is unclear whether these reports are due to the underlying hypertension, its treatment, or to a specific drug effect.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The available information is inadequate to rule out adverse drug effects on the unborn and newborn child. Therefore any use in pregnancy requires a very careful individual risk benefit assessment and should only be considered if all other treatment options are either not indicated or have failed to be efficacious.</p><p>&nbsp;</p><p>Acute pulmonary oedema has been observed when calcium channel blockers, among others nifedipine, have been used as a tocolytic agent during pregnancy (see section 4.8), especially in cases of multiple pregnancy (twins or more), with the intravenous route and/or concomitant use of beta-2 agonists.</p><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Breast-feeding</u></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nifedipine is excreted in the breast milk. The nifedipine concentration in the milk is almost comparable with mother serum concentration. For immediate release formulations, it is proposed to delay breast-feeding or milk expression for 3 to 4 hours after drug administration to decrease the nifedipine exposure to the infant (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><u>Fertility</u></strong></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In single cases of <em>in vitro</em> fertilisation calcium antagonists like nifedipine have been associated with reversible biochemical changes in the spermatozoa&rsquo;s head section that may result in impaired sperm function. In those men who are repeatedly unsuccessful in fathering a child by <em>in vitro</em> fertilisation, and where no other explanation can be found, calcium antagonists like nifedipine should be considered as possible causes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reactions to the drug, which vary in intensity from individual to individual, may impair the ability to drive or to operate machinery (see Section 4.8). This applies particularly at the start of treatment, on changing the medication and in combination with alcohol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse drug reactions (ADRs) based on placebo-controlled studies with nifedipine sorted by CIOMS III categories of frequency (clinical trial data base: nifedipine n&nbsp;=&nbsp;2,661; placebo n = 1,486; status: 22 Feb 2006 and the ACTION study: nifedipine n&nbsp;=&nbsp;3,825; placebo n = 3,840) are listed below:</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADRs listed under &quot;common&quot; were observed with a frequency below 3% with the exception of oedema (9.9%) and headache (3.9%).</p><p>&nbsp;</p><p>The frequencies of ADRs reported with nifedipine-containing products are summarised in the table below. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as common (&ge;1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100) and rare (&ge;&nbsp;1/10,000 to &lt; 1/1,000). The ADRs identified only during the ongoing postmarketing surveillance, and for which a frequency could not be estimated, are listed under &ldquo;Not known&rdquo;.<em> </em></p><p><strong>&nbsp;</strong></p><table cellspacing="0" cellpadding="0" border="1" style="width:600px"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class (MedDRA)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Not Known</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Blood and Lymphatic System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Agranulocytosis</p><p>Leucopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reaction</p><p>Allergic oedema/angioedema (incl. larynx oedema<sup>*</sup>)</p></td><td style="vertical-align:top"><p>Pruritus</p><p>Urticaria</p><p>Rash</p></td><td style="vertical-align:top"><p>Anaphylactic/ anaphylactoid reaction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anxiety reactions</p><p>Sleep disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nerv</strong><strong>ous System Disorders</strong></p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Vertigo</p><p>Migraine</p><p>Dizziness</p><p>Tremor</p></td><td style="vertical-align:top"><p>Par-/Dysaesthesia</p></td><td style="vertical-align:top"><p>Hypoaesthesia</p><p>Somnolence</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual disturbances</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Eye pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia</p><p>Palpitations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Chest pain</p><p>(Angina pectoris)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top"><p>Oedema (incl.</p><p>peripheral</p><p>oedema)</p><p>Vasodilatation</p></td><td style="vertical-align:top"><p>Hypotension</p><p>Syncope</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nosebleed</p><p>Nasal congestion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea</p><p>Pulmonary oedema**</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal Disorders</strong></p></td><td style="vertical-align:top"><p>Constipation</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gastrointestinal and abdominal pain</p><p>Nausea</p><p>Dyspepsia</p><p>Flatulence</p><p>Dry mouth</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gingival hyperplasia</p></td><td style="vertical-align:top"><p>Bezoar</p><p>Dysphagia</p><p>Intestinal obstruction</p><p>Intestinal ulcer</p><p>Vomiting</p><p>Gastroesophageal sphincter insufficiency</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Transient increase in liver enzymes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Jaundice</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erythema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Toxic Epidermal Necrolysis</p><p>Photosensitivity allergic reaction</p><p>Palpable purpura</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and Connective Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle cramps</p><p>Joint swelling</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia</p><p>Myalgia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and Urinary Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Polyuria</p><p>Dysuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive System and Breast Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders and Administration Site Conditions</strong></p></td><td style="vertical-align:top"><p>Feeling unwell</p></td><td style="vertical-align:top"><p>Unspecific pain</p><p>Chills</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;&nbsp;</p><p>* = may result in life-threatening outcome</p><p>**cases have been reported when used as tocolytic during pregnancy (see section 4.6)</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In dialysis patients with malignant hypertension and hypovolaemia a distinct fall in blood pressure can occur as a result of vasodilation.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Reporting of suspected adverse reactions</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To report any side effect(s):</strong></p><p>National Pharmacovigilance and Drug Safety Center (NPC).</p><p>Fax: + 966 - 11 - 205 - 7662.</p><p>Call NPC at +966 - 11 - 2038222,</p><p>Ext.: 2317 - 2356 - 2353 - 2354 - 2334 - 2340.</p><p>Toll - free: 8002490000.</p><p>E - mail: npc.drug@sfda.gov.sa.</p><p>Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Symptoms</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following symptoms are observed in cases of severe nifedipine intoxication:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disturbances of consciousness to the point of coma, a drop in blood pressure, tachycardia, bradycardia, hyperglycaemia, metabolic acidosis, hypoxia, cardiogenic shock with pulmonary oedema.</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As far as treatment is concerned, elimination of nifedipine and the restoration of stable cardiovascular conditions have priority. Elimination must be as complete as possible, including the small intestine, to prevent the otherwise inevitable subsequent absorption of the active substance.&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The benefit of gastric decontamination is uncertain.</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consider activated charcoal (50 g for adults, 1 g/kg for children) if the patient presents within 1 hour of ingestion of a potentially toxic amount.</p><p>Although it may seem reasonable to assume that late administration of activated charcoal may be beneficial for sustained release (SR, MR) preparations there is no evidence to support this.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alternatively consider gastric lavage in adults within 1 hour of a potentially life-threatening overdose.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consider further doses of activated charcoal every 4 hours if a clinically significant amount of a sustained release preparation has been ingested with a single dose of an osmotic laxative (e.g. sorbitol, lactulose or magnesium sulfate).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asymptomatic patients should be observed for at least 4 hours after ingestion and for 12 hours if a sustained release preparation has been taken.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haemodialysis serves no purpose as nifedipine is not dialysable, but plasmapheresis is advisable (high plasma protein binding, relatively low volume of distribution).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension as a result of cardiogenic shock and arterial vasodilatation can be treated with calcium (10-20 ml of a 10 % calcium gluconate solution administered intravenously over 5-10 minutes).&nbsp; If the effects are inadequate, the treatment can be continued, with ECG monitoring.&nbsp; If an insufficient increase in blood pressure is achieved with calcium, vasoconstricting sympathomimetics such as dopamine or noradrenaline should be administered.&nbsp; The dosage of these drugs should be determined by the patient&#39;s response.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Symptomatic bradycardia may be treated with atropine, beta-sympathomimetics or a temporary cardiac pacemaker, as required.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp;Additional fluids should be administered with caution to avoid cardiac overload.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;&nbsp;Pharmacotherapeutic group: selective calcium channel blockers with mainly vascular effect, dihydropyridine derivatives, ATC code: C08CA05</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nifedipine is a calcium antagonist of the 1,4-dihydropyridine type. Calcium antagonists reduce the transmembranal influx of calcium ions through the slow calcium channel into the cell. As a specific and potent calcium antagonist, nifedipine acts particularly on the cells of the myocardium and the smooth muscle cells of the coronary arteries and the peripheral resistance vessels. The main action of nifedipine is to relax arterial smooth muscle, both in the coronary and peripheral circulation.&nbsp; The Adalat LA tablet is formulated to achieve controlled delivery of nifedipine in a release profile sufficient to enable once-daily administration to be effective in clinical use.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In hypertension, the main action of nifedipine is to cause peripheral vasodilatation and thus reduce peripheral resistance.&nbsp; Nifedipine administered once-daily provides 24-hour control of raised blood pressure.&nbsp; Nifedipine causes reduction in blood pressure such that the percentage lowering is proportional to its initial level. In normotensive individuals, nifedipine has little or no effect on blood pressure.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In angina, Adalat LA reduces peripheral and coronary vascular resistance, leading to an increase in coronary blood flow, cardiac output and stroke volume, whilst decreasing after-load.&nbsp; Additionally, nifedipine dilates submaximally both clear and atherosclerotic coronary arteries, thus protecting the heart against coronary artery spasm and improving perfusion to the ischaemic myocardium.&nbsp; Nifedipine reduces the frequency of painful attacks and the ischaemic ECG changes irrespective of the relative contribution from coronary artery spasm or atherosclerosis.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In a multi-national, randomised, double-blind, prospective study involving 6321 hypertensive patients with at least one additional risk factor followed over 3 to 4.8 years, Adalat LA 30 and 60 (nifedipine GITS) were shown to reduce blood pressure to a comparable degree as a standard diuretic combination.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><u>Paediatric population</u></em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Limited information on comparison of nifedipine with other antihypertensives is available for both acute hypertension and long-term hypertension with different formulations in different dosages. Antihypertensive effects of nifedipine have been demonstrated but dose recommendations, long term safety and effect on cardiovascular outcome remain unestablished. Pediatric dosing forms are lacking.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General characteristics:</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adalat LA tablets are formulated to provide nifedipine at an approximately constant rate over 24 hours. Nifedipine is released from the tablet at a zero-order rate by a membrane-controlled, osmotic push-pull process. The pharmacokinetic profile of this formulation is characterized by low peak-trough fluctuation. 0-24 hour plasma concentration versus time profiles at steady state are plateau-like, rendering the Adalat LA tablet appropriate for once-a-day administration.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The delivery rate is independent of gastrointestinal pH or motility. Upon swallowing, the biologically inert components of the tablet remain intact during gastrointestinal transit and are eliminated in the faeces as an insoluble shell.</p><p>&nbsp;</p><p><em><u>Absorption</u></em></p><p>Orally administered nifedipine is almost completely absorbed in the gastro-intestinal tract.&nbsp; The systemic availability of orally administered nifedipine immediate release formulations (nifedipine capsules) is 45&ndash;56% owing to a first pass effect. At steady-state, the bioavailability of Adalat LA tablets ranges from 68-86% relative to Adalat capsules.&nbsp; Administration in the presence of food slightly alters the early rate of absorption but does not influence the extent of drug availability.</p><p>&nbsp;</p><p><em><u>Distribution</u></em></p><p>Nifedipine is about 95% bound to plasma protein (albumin). The distribution half-life after intravenous administration has been determined to be 5 to 6 minutes.</p><p>&nbsp;</p><p><em><u>Biotransformation</u></em></p><p>After oral administration, nifedipine is metabolised in the gut wall and in the liver, primarily by oxidative processes. These metabolites show no pharmacodynamic activity. Nifedipine is eliminated in the form of its metabolites, predominantly via the kidneys, with approximately 5-15% being excreted via the bile in the faeces.&nbsp; Non-metabolised nifedipine can be detected only in traces (below 0.1%) in the urine.&nbsp;</p><p>&nbsp;</p><p><em><u>Elimination</u></em></p><p>The terminal elimination half-life is 1.7 to 3.4 h in conventional formulations (nifedipine capsules). The terminal half-life following Adalat LA administration does not represent a meaningful parameter as a plateau-like plasma concentration is maintained during release from the tablets and absorption. After release and absorption of the last dose the plasma concentration finally declines with an elimination half-life as seen in conventional formulations.</p><p><em>&nbsp;</em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Characteristics in patients:</em></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There are no significant differences in the pharmacokinetics of nifedipine between healthy subjects and subjects with renal impairment.&nbsp; Therefore, dosage adjustment is not needed in these patients.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with hepatic impairment, the elimination half-life is distinctly prolonged and the total clearance is reduced.&nbsp; Owing to the duration of action of the formulation, Adalat LA should not be administered in these patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazards for humans based on conventional studies of single and repeated dose toxicity, genotoxicity and carcinogenic potential.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Following acute oral and intravenous administration of nifedipine in various animal species, the following LD<sub>50</sub> (mg/kg) values were obtained:</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="vertical-align:top"><p>Mouse:</p></td><td style="vertical-align:top"><p>Oral: 494 (421-572)*;</p></td><td style="vertical-align:top"><p>i.v.:&nbsp; 4.2 (3.8-4.6)*.</p></td></tr><tr><td style="vertical-align:top"><p>Rat:</p></td><td style="vertical-align:top"><p>Oral:&nbsp; 1022 (950-1087)*;</p></td><td style="vertical-align:top"><p>i.v.:&nbsp; 15.5 (13.7-17.5)*.</p></td></tr><tr><td style="vertical-align:top"><p>Rabbit</p></td><td style="vertical-align:top"><p>Oral:&nbsp; 250-500;</p></td><td style="vertical-align:top"><p>i.v.:&nbsp; 2-3.</p></td></tr><tr><td style="vertical-align:top"><p>Cat:</p></td><td style="vertical-align:top"><p>Oral:&nbsp; ~ 100;</p></td><td style="vertical-align:top"><p>i.v.:&nbsp; 0.5-8.</p></td></tr><tr><td style="vertical-align:top"><p>Dog:</p></td><td style="vertical-align:top"><p>Oral:&nbsp;&nbsp; &gt; 250;</p></td><td style="vertical-align:top"><p>i.v.:&nbsp; 2-3.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* 95% confidence interval.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In subacute and subchronic toxicity studies in rats and dogs, nifedipine was tolerated without damage at doses of up to 50&nbsp;mg/kg (rats) and 100&nbsp;mg/kg (dogs) p.o. over periods of thirteen and four weeks, respectively.&nbsp; Following intravenous administration, dogs tolerated up to 0.1&nbsp;mg/kg nifedipine for six days without damage.&nbsp; Rats tolerated daily intravenous administration of 2.5&nbsp;mg/kg nifedipine over a period of three weeks without damage.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In chronic toxicity studies in dogs with treatment lasting up to one year, nifedipine was tolerated without damage at doses up to and including 100&nbsp;mg/kg p.o.&nbsp; In rats, toxic effects occurred at concentrations above 100&nbsp;ppm in the feed (approximately 5-7&nbsp;mg/kg bodyweight).</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In a carcinogenicity study in rats (two years), there was no evidence of a carcinogenic effect of nifedipine.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nifedipine has been shown to produce teratogenic findings in rats, mice and rabbits, including digital anomalies, malformation of the extremities,<strong> </strong>cleft palates, cleft sternum and malformation of the ribs.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digital anomalies and malformation of the extremities are possibly a result of compromised uterine blood flow, but have also been observed in animals treated with nifedipine solely after the end of the organogenesis period.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nifedipine administration was associated with a variety of embryotoxic, placentotoxic and foetotoxic effects, including stunted foetuses (rats, mice, rabbits), small placentas and underdeveloped chorionic villi (monkeys), embryonic and foetal deaths (rats, mice, rabbits) and prolonged pregnancy/decreased neonatal survival (rats; not evaluated in other species). The risk to humans cannot be ruled out if a sufficiently high systemic exposure is achieved, however, all of the doses associated with the teratogenic, embryotoxic or foetotoxic effects in animals were maternally toxic and were several times the recommended maximum dose for humans.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In <em>in vitro</em> and <em>in vivo</em> tests, nifedipine has not been associated with mutagenic properties.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Tablet Core</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Polyethylene oxide</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypromellose (5 cp)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Magnesium stearate</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium chloride</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ferric oxide, red (E172)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Coating</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cellulose acetate</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Macrogol (3350)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydroxypropylcellulose</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypromellose (3 cp)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Propylene glycol</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypromellose (5 cp)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide (E171)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ferric oxide, red (E172)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Polish and Print</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Black ink for printing Opacode S-1-17823</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Contains: iron oxide black (E172) and Shellac)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                		PP blister packs:		4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original container. The tablets should be protected from strong light. Do not store above 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister packs composed of polyamide/aluminium/polyvinyl chrloride / aluminium foil - in folding boxes, containing 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No additional information</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer AG,
Berlin, Germany.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	10/08/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>